ArticleAntibiotics (Basel, Switzerland)2021
A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model.The Journal of infectious diseases · 2026Article
- Article
- ComparativeJAC-antimicrobial resistance · 2025Article
- Sulbactam for carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics.Pathogens (Basel, Switzerland) · 2025Review
- A National Surveillance of the Antibiotic Susceptibility ofAntibiotics (Basel, Switzerland) · 2025Article
- A new approach to treat carbapenem resistantIDCases · 2025Article
- Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024Review
- Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Drug‑resistantExperimental and therapeutic medicine · 2023Review
- Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.International journal of antimicrobial agents · 2023Article
- Zidebactam restores sulbactam susceptibility against carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
- Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists.Infectious diseases and therapy · 2021Review
- Systematic Review of Antimicrobial Combination Options for Pandrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/relebactam combination were tested against 187 multi-drug resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.